We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Spiritus Mundi Plc | SPMU | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.25 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.25 | 3.25 |
| Industry Sector |
|---|
| GENERAL FINANCIAL |
| Top Posts |
|---|
Posted at 26/2/2023 13:07 by hedgehog 100 Current share price 26th. February 2023: 1.75p49,300,000 shares in issue Market capitalisation: £862,750. "About Us Spiritus Mundi plc is a Special Purpose Acquisition Company (SPAC) incorporated in the United Kingdom. Our mission is to identify and partner with business that complements the experience and skills of our management team to build out investments in close alignment of our acquisition target in healthcare industry. The Company is a newly formed entity established to seek acquisition opportunities in the Healthcare services sector focusing primarily on pathology and laboratory testing, clinical diagnostics, and digital health. Together, the Directors have many years of business experience of operating in the healthcare and financial services industry, particularly in the areas of clinical diagnostic laboratory services, acquisitions, capital markets and trading and they have established a network of contacts internationally within the sector. The Company will utilise independent third parties to provide expert advice where necessary." 08/07/2022 06:00 UK Regulatory (RNS & others) Spiritus Mundi PLC Admission to trading on the London Stock Exchange LSE:SPMU Spiritus Mundi Plc "Spiritus Mundi plc ("Spiritus Mundi" or the "Company"), a Special Purpose Acquisition Company (SPAC) which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector, is pleased to announce that at 8:00 a.m. today its entire issued ordinary share capital, consisting of 49,300,000 ordinary shares, will be admitted to the Standard Listing segment of the Official List of the Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange ("Admission") under the ticker "SPMU" and ISIN GB00BMHR3L94. Spiritus Mundi was established in 2021 by Zaccheus Peh, an experienced developer of clinical diagnostics, laboratory services and medical services businesses, as a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector to include (but not limited to): -- Clinical laboratory services (clinical lab); -- Clinical Diagnostics (PCR and blood test); and -- Digital Health (Healthcare IT platform). The Company's board, detailed in the appendix below, through their established global network of contacts, have identified a number of potentially promising acquisitions. The Company does not currently have any specific initial acquisition under consideration. The Company will seek to create an attractive income-generating business and increase shareholder value through the operation of the acquired business or businesses. The board will be focussed on the identification and acquisition of companies which have one or more of the following characteristics: -- are run by a management team with a strong track record of generating growth for shareholders and a proven experienced business record; -- have attractive commercial prospects within the clinical diagnostics sector in general; -- will have the capability to further develop their activities in a post Covid world; and -- have revenues which offer the potential for near-term positive cash flows. An acquisition (and potentially, any subsequent acquisitions or investments made by the Company) is likely to be treated as a reverse takeover for the purposes of Chapter 5 of the Listing Rules and the Company will need to seek re-admission of Spiritus Mundi and its acquired subsidiaries to listing on the Official List and trading on the London Stock Exchange or to another stock exchange. Subsequent acquisitions may also be treated as reverse takeovers depending on their size and nature. Additional funding may be needed in the future to acquire further business and provide working capital. Zaccheus Peh, Non-Executive Chairman of Spiritus Mundi, said: "I am delighted that Spiritus Mundi is listing on the London Stock Exchange. We believe there are attractive acquisition opportunities in our chosen sectors of laboratory and diagnostic testing, and digital healthcare, particularly in light of how the COVID -19 pandemic has changed the sector dynamics. We plan to use Spiritus Mundi as a vehicle to acquire one or more exciting businesses in these areas in order to generate attractive returns for our shareholders." Total Voting Rights Following Admission total number of Ordinary Shares with voting rights in the Company is 49,300,000. The Company does not hold any shares in treasury and all of the ordinary shares have equal voting rights. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Prospectus The Company's Prospectus was published on 30 June 2022 and is available to view on the Company's website: www.spiritusmundiplc For further information please contact: Spiritus Mundi plc Via IFC Zaccheus Peh (Non-Executive Chairman) VSA Capital (Financial Adviser) +44 (0) 203 005 5000 Andrew Raca, Pascal Wiese ipo@vsacapital.com Stanford Capital Partners (Broker) Patrick Claridge / John Howes +44 (0)20 3650 3650 IFC Advisory Limited (Financial PR and IR) +44 (0) 203 934 6630 Tim Metcalfe, Florence Chandler spiritusmundi@invest From Spiritus Mundi's prospectus dated 30th. June 2022:- "On 28 April 2021, the Company undertook the Founder Subscription round to raise gross proceeds of £50,000 at a price of £0.01. On 12 July 2021, the Company completed the Friends & Family Subscription round to raise gross proceeds of £1,161,000 at a price of £0.03. On 26 April 2022, the Company completed the Subscription to raise gross proceeds of £280,000 at a price of £0.05. Following the Subscription, the Company will have 49,300,000 Ordinary Shares in issue. The Subscription Shares will rank pari passu with the Existing Ordinary Shares." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
